The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.
Andreas Schneeweiss
Consultant or Advisory Role - Lilly; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - Lilly
Amparo Ruiz
No relevant relationships to disclose
Alexey Manikhas
No relevant relationships to disclose
Alberto Bottini
No relevant relationships to disclose
Pedro Sanchez Rovira
No relevant relationships to disclose
Kambiz Mansouri
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Gbenga Kazeem
Employment or Leadership Position - Lilly
Thomas Bauknecht
Employment or Leadership Position - Lilly
Stock Ownership - Lilly